OR6C64P

Across TCGA pan-cancer cohorts, OR6C64P RNA is linked to patient survival in 9 of 34 cancer types, making it the most broadly survival-associated OR6C64P data layer.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher OR6C64P RNA is associated with worse overall survival. In most high-consensus cancer types, elevated OR6C64P expression acts as an unfavorable survival marker.

LIHC, ESCA, and COAD are the cancer types where OR6C64P RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Tertile	II,III,IV	0.055	0.720	<.001	120	view →
ESCA	OS	Tertile	All	0.198	0.872	.003	72	view →
COAD	OS	Tertile	II,III,IV	0.184	0.792	<.001	72	view →
ACC	OS	Tertile	All	0.113	0.822	<.001	63	view →
STAD	DFS	Tertile	All	0.421	0.739	.001	30	view →
LGG	DFS	Tertile	All	0.294	0.746	<.001	27	view →
DLBC	OS	Tertile	III,IV	0.175	0.874	.025	27	view →
UCEC	DFS	Tertile	IV	0.206	0.704	.033	18	view →
SARC	DFS	Tertile	All	0.148	0.594	.016	9	view →

Pink = unfavorable, green = favorable. Showing the 9 strongest of 9 lineages.

OR6C64P–LIHC (OS)

Open the LIHC breakdown →